Intercept Pharmaceuticals, Inc. (ICPT)

Stock Price: $47.09 USD 0.57 (1.23%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
The Motley Fool - 4 days ago

An approval pathway for OCA in treating NASH still exists. But it appears to be a steeper path.

Zacks Investment Research - 5 days ago

Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

Investors Business Daily - 5 days ago

The Food and Drug Administration rejected Intercept Pharmaceuticals' therapy for an obesity-linked liver disease — sending ICPT stock crashing on Monday. Shares hit a seven-year low.

Business Wire - 5 days ago

LOS ANGELES--(BUSINESS WIRE)---- $ICPT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NA...

Benzinga - 5 days ago

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares were retreating sharply Monday on the back of an FDA rejection of its lead non-alcoholic steatohepatitis drug.

Invezz - 6 days ago

Shares of Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) plunged over 40% after the U.S. U.S. Food and Drug Administration (FDA) declined to approve the firm’s therapy for liver disease.

The Motley Fool - 6 days ago

The pharmaceutical company's attempt to get obeticholic acid approved for the lucrative non-alcoholic steatohepatitis market has hit a (perhaps temporary) roadblock.

The Motley Fool - 6 days ago

Shares are taking a step back after the FDA rejected the company's NASH candidate.

24/7 Wall Street - 6 days ago

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) says it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) fo...

Market Watch - 6 days ago

Intercept Pharmaceuticals Inc. shares ICPT, -2.65% tumbled more than 30% in premarket trade Monday, after the company said it has received a U.S.

GlobeNewsWire - 6 days ago

Conference call scheduled for 8:30 a.m. ET today Conference call scheduled for 8:30 a.m. ET today

The Motley Fool - 2 weeks ago

These two companies are going after the same target, but which one should you bet on today?

Stocks mentioned: ICPT, MDGL
The Motley Fool - 2 weeks ago

Here's why this leader in treating progressive non-viral liver disease is, in fact, a solid buy.

Zacks Investment Research - 3 weeks ago

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 4 weeks ago

Intercept Pharmaceuticals: Undervalued Ahead Of An Eventful Period

The Motley Fool - 1 month ago

This summer will start against a backdrop of unprecedented uncertainty, so investors looking to add to their portfolios will want to focus on rock-solid companies like these.

Stocks mentioned: CSCO, ICPT, NOW, OKTA, USB
The Motley Fool - 1 month ago

This drug developer has first-mover advantage in an untapped $35 billion indication.

Zacks Investment Research - 1 month ago

The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.

The Motley Fool - 1 month ago

Investors are feeling more uncertainty about whether obeticholic acid will be approved as a treatment for liver fibrosis due to nonalcoholic steatohepatitis.

The Motley Fool - 1 month ago

The company received some bad news from the FDA.

Investors Business Daily - 1 month ago

An unexpected delay for Intercept Pharmaceuticals' liver-disease treatment led ICPT stock to crumble on Friday. Intercept is working on obeticholic acid in nonalcoholic steatohepatitis.

GlobeNewsWire - 1 month ago

NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics t...

The Motley Fool - 1 month ago

This trio of uniquely focused exchange-traded funds could make you a lot of money.

Stocks mentioned: CLOU, GDX, ICPT, SBIO
The Motley Fool - 1 month ago

Which stock wins in a matchup between these two biotechs?

Stocks mentioned: GILD, ICPT
Zacks Investment Research - 1 month ago

Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.

Seeking Alpha - 1 month ago

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q1 2020 Results - Earnings Call Transcript

Benzinga - 1 month ago

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) rose 2.5% after the company reported Q1 results.

Zacks Investment Research - 1 month ago

Intercept (ICPT) delivered earnings and revenue surprises of 2.72% and 6.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 1 month ago

A recovery from a March decline and the possibility of a megablockbuster drug sent shares up 40%.

The Motley Fool - 2 months ago

Growth, value, and income stocks are on sale for investors this month.

Stocks mentioned: ICPT, T, WFC
24/7 Wall Street - 2 months ago

The coronavirus pandemic has cast the spotlight on the world of biotechnology stocks as researchers search for not only a vaccine, but for additional drugs that can help in the treatment of th...

Stocks mentioned: GILD, ICPT, ITCI, KPTI, OVID
The Motley Fool - 2 months ago

Bargains abound, even among higher-growth small-cap stocks.

Stocks mentioned: ICPT, PING, SSRM
The Motley Fool - 2 months ago

Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.

Stocks mentioned: HRTX, ICPT
The Motley Fool - 2 months ago

Intercept's stock is ridiculously cheap after last month's sharp pullback.

Seeking Alpha - 3 months ago

Intercept Pharmaceuticals: Your Transformative Year

Zacks Investment Research - 3 months ago

Intercept (ICPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GuruFocus - 3 months ago

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belon...

Stocks mentioned: BMY, GNFT, ICPT, MDGL, NVS, PTCT, RHHBY
Zacks Investment Research - 3 months ago

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 3 months ago

These under-the-radar companies now look like big-time bargains.

Stocks mentioned: AEO, ICPT, IIPR
Seeking Alpha - 3 months ago

Intercept Pharmaceuticals: A High-Risk High-Gain Pick For 2020

Investors Business Daily - 3 months ago

A growing number of Covid-19 cases could frustrate biotech companies' efforts to enroll patients in clinical studies, an analyst said Tuesday.

Stocks mentioned: CRBP, GILD, GLPG, ICPT, PTCT
The Motley Fool - 3 months ago

These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.

Stocks mentioned: ICPT, MDGL
Zacks Investment Research - 4 months ago

Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.

Seeking Alpha - 4 months ago

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 4 months ago

The company's lead drug, Ocaliva, brought in $249.6 million last year.

Zacks Investment Research - 4 months ago

Intercept (ICPT) delivered earnings and revenue surprises of -16.80% and 4.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 4 months ago

Despite only having one product on the market, Intercept Pharmaceuticals is worth considering.

Zacks Investment Research - 5 months ago

Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.

The Motley Fool - 5 months ago

What does the future hold for these two biotech stocks?

Stocks mentioned: GILD, ICPT
GlobeNewsWire - 5 months ago

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics ...

Latest From StockTwits